Logo image of IMRX

IMMUNEERING CORP - CLASS A (IMRX) Stock Fundamental Analysis

USA - NASDAQ:IMRX - US45254E1073 - Common Stock

6.89 USD
+0.27 (+4.08%)
Last: 11/7/2025, 8:00:02 PM
6.9401 USD
+0.05 (+0.73%)
After Hours: 11/7/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, IMRX scores 3 out of 10 in our fundamental rating. IMRX was compared to 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMRX as it has an excellent financial health rating, but there are worries on the profitability. IMRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMRX has reported negative net income.
In the past year IMRX has reported a negative cash flow from operations.
In the past 5 years IMRX always reported negative net income.
IMRX had a negative operating cash flow in each of the past 5 years.
IMRX Yearly Net Income VS EBIT VS OCF VS FCFIMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

IMRX has a Return On Assets of -121.73%. This is in the lower half of the industry: IMRX underperforms 79.66% of its industry peers.
IMRX has a Return On Equity of -147.44%. This is in the lower half of the industry: IMRX underperforms 62.90% of its industry peers.
Industry RankSector Rank
ROA -121.73%
ROE -147.44%
ROIC N/A
ROA(3y)-69.7%
ROA(5y)-54.72%
ROE(3y)-84.13%
ROE(5y)-64.35%
ROIC(3y)N/A
ROIC(5y)N/A
IMRX Yearly ROA, ROE, ROICIMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

IMRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMRX Yearly Profit, Operating, Gross MarginsIMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

IMRX has more shares outstanding than it did 1 year ago.
IMRX has more shares outstanding than it did 5 years ago.
IMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMRX Yearly Shares OutstandingIMRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
IMRX Yearly Total Debt VS Total AssetsIMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

IMRX has an Altman-Z score of 16.95. This indicates that IMRX is financially healthy and has little risk of bankruptcy at the moment.
IMRX has a better Altman-Z score (16.95) than 88.89% of its industry peers.
There is no outstanding debt for IMRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.95
ROIC/WACCN/A
WACCN/A
IMRX Yearly LT Debt VS Equity VS FCFIMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

IMRX has a Current Ratio of 7.48. This indicates that IMRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IMRX (7.48) is better than 71.94% of its industry peers.
A Quick Ratio of 7.48 indicates that IMRX has no problem at all paying its short term obligations.
IMRX has a Quick ratio of 7.48. This is in the better half of the industry: IMRX outperforms 72.50% of its industry peers.
Industry RankSector Rank
Current Ratio 7.48
Quick Ratio 7.48
IMRX Yearly Current Assets VS Current LiabilitesIMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.05% over the past year.
EPS 1Y (TTM)1.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IMRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.00% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.31%
EPS Next 2Y4.85%
EPS Next 3Y3.92%
EPS Next 5Y11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMRX Yearly Revenue VS EstimatesIMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
IMRX Yearly EPS VS EstimatesIMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMRX Price Earnings VS Forward Price EarningsIMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMRX Per share dataIMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.85%
EPS Next 3Y3.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNEERING CORP - CLASS A

NASDAQ:IMRX (11/7/2025, 8:00:02 PM)

After market: 6.9401 +0.05 (+0.73%)

6.89

+0.27 (+4.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners9.29%
Inst Owner Change116.45%
Ins Owners14.55%
Ins Owner Change4.25%
Market Cap397.28M
Revenue(TTM)N/A
Net Income(TTM)-61.70M
Analysts83.64
Price Target16.93 (145.72%)
Short Float %15.76%
Short Ratio3.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.5%
Min EPS beat(2)-22.81%
Max EPS beat(2)21.82%
EPS beat(4)3
Avg EPS beat(4)6.06%
Min EPS beat(4)-22.81%
Max EPS beat(4)21.82%
EPS beat(8)6
Avg EPS beat(8)6.79%
EPS beat(12)10
Avg EPS beat(12)8.23%
EPS beat(16)11
Avg EPS beat(16)6.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)49.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.25%
EPS NY rev (3m)9.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.49
P/tB 11.41
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.83
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0
BVpS0.73
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -121.73%
ROE -147.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.7%
ROA(5y)-54.72%
ROE(3y)-84.13%
ROE(5y)-64.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.48
Quick Ratio 7.48
Altman-Z 16.95
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)127.9%
Cap/Depr(5y)150.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.89%
EPS Next Y21.31%
EPS Next 2Y4.85%
EPS Next 3Y3.92%
EPS Next 5Y11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.81%
EBIT Next 3Y-26.85%
EBIT Next 5Y-22.09%
FCF growth 1Y-15.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.96%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNEERING CORP - CLASS A / IMRX FAQ

What is the ChartMill fundamental rating of IMMUNEERING CORP - CLASS A (IMRX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMRX.


Can you provide the valuation status for IMMUNEERING CORP - CLASS A?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNEERING CORP - CLASS A (IMRX). This can be considered as Overvalued.


How profitable is IMMUNEERING CORP - CLASS A (IMRX) stock?

IMMUNEERING CORP - CLASS A (IMRX) has a profitability rating of 0 / 10.


How financially healthy is IMMUNEERING CORP - CLASS A?

The financial health rating of IMMUNEERING CORP - CLASS A (IMRX) is 8 / 10.


Can you provide the expected EPS growth for IMRX stock?

The Earnings per Share (EPS) of IMMUNEERING CORP - CLASS A (IMRX) is expected to grow by 21.31% in the next year.